Niacin inhibits vascular inflammation via the induction of heme oxygenase-1

Circulation

Volumn 125, Issue 1, 2012, Pages 150-158

  Wu, Ben J ^a   Chen, Kang ^a,b,c   Barter, Philip J ^a,b   Rye, Kerry Anne ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

cardiovascular diseases; drugs; endothelium; inflammation

Indexed keywords

BILIRUBIN; HEME OXYGENASE 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINIC ACID; PROTOPORPHYRIN TIN; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERY ENDOTHELIUM; ARTICLE; BILIRUBIN BLOOD LEVEL; COMMON CAROTID ARTERY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INDUCTION; HEART PROTECTION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VASCULITIS;

ANIMALS; ATHEROSCLEROSIS; CELLS, CULTURED; CORONARY VESSELS; ENZYME INDUCTION; HEME OXYGENASE-1; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; NIACIN; RABBITS;

EID: 84855381655     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.053108     Document Type: Article

References (40)

1. Brooks EL, Kuvin JT, Karas RH. Niacin's role in the statin era. Expert Opin Pharmacother. 2010;11:2291-2300.
2. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231: 360-381.
3. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255. (Pubitemid 17208898)
4. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113-2122.
5. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis. 2009;202:68-75.
6. Chen J, Cui X, Zacharek A, Jiang H, Roberts C, Zhang C, Lu M, Kapke A, Feldkamp CS, Chopp M. Niaspan increases angiogenesis and improves functional recovery after stroke. Ann Neurol. 2007;62:49-58. (Pubitemid 47235280)
7. Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol. 2010;30:968-975.
8. Li C, Hossieny P, Wu BJ, Qawasmeh A, Beck K, Stocker R. Pharmacologic induction of heme oxygenase-1. Antioxid Redox Signal. 2007;9: 2227-2239. (Pubitemid 350059011)
9. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev. 2006;86:583-650.
10. Maines MD, Gibbs PE. 30 some years of heme oxygenase: from a molecular wrecking ball to a mesmerizing trigger of cellular events. Biochem Biophys Res Commun. 2005;338:568-577. (Pubitemid 41540604)
11. Juan SH, Lee TS, Tseng KW, Liou JY, Shyue SK, Wu KK, Chau LY. Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2001;104:1519-1525. (Pubitemid 32917345)
12. Wu BJ, Kathir K, Witting PK, Beck K, Choy K, Li C, Croft KD, Mori TA, Tanous D, Adams MR, Lau AK, Stocker R. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J Exp Med. 2006;203:1117-1127.
13. Tulis DA, Durante W, Liu X, Evans AJ, Peyton KJ, Schafer AI. Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injuryinduced vascular neointima formation. Circulation. 2001;104: 2710-2715. (Pubitemid 33108139)
14. Otterbein LE, Soares MP, Yamashita K, Bach FH. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol. 2003;24: 449-455. (Pubitemid 36928103)
15. Wu BJ, Midwinter RG, Cassano C, Beck K, Wang Y, Changsiri D, Gamble JR, Stocker R. Heme oxygenase-1 increases endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2009;29:1537-1542.
16. Poss KD, Tonegawa S. Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci U S A. 1997;94:10925-10930. (Pubitemid 27430837)
17. Stocker R. Antioxidant activities of bile pigments. Antioxid Redox Signal. 2004;6:841-849. (Pubitemid 39237937)
18. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem. 1994;40:18-23. (Pubitemid 24050206)
19. Fromke VL, Miller D. Constitutional hepatic dysfunction (CHD; Gilbert's disease): a review with special reference to a characteristic increase and prolongation of the hyperbilirubinemic response to nicotinic acid. Medicine. 1972;51:451-464.
20. Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, Brody J. Efficacy and safety of an extended-release niacin (niaspan): a long-term study. Am J Cardiol. 1998;82:74U-81U. (Pubitemid 29044485)
21. Nash MS, Lewis JE, Dyson-Hudson TA, Szlachcic Y, Yee F, Mendez AJ, Spungen AM, Bauman WA. Safety, tolerance, and efficacy of extendedrelease niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial. Arch Phys Med Rehabil. 2011;92:399-410.
22. Ohkubo H, Musha H, Okuda K. Studies on nicotinic acid interaction with bilirubin metabolism. Dig Dis Sci. 1979;24:700-704. (Pubitemid 10209250)
23. Bakken AF, Thaler MM, Schmid R. Metabolic regulation of heme catabolism and bilirubin production. I. Hormonal control of hepatic heme oxygenase activity. J Clin Invest. 1972;51:530-536.
24. Nicholls SJ, Dusting GJ, Cutri B, Bao S, Drummond GR, Rye KA, Barter PJ. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 2005;111:1543-1550. (Pubitemid 40470651)
25. Deng YM, Wu BJ, Witting PK, Stocker R. Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. Circulation. 2004;110:1855-1860. (Pubitemid 39299229)
26. Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009;104:74-81.
27. Knopp RH, Alagona P, Davidson M, Goldberg AC, Kafonek SD, Kashyap M, Sprecher D, Superko HR, Jenkins S, Marcovina S. Equivalent efficacy of a time-release form of niacin (niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998;47:1097-1104. (Pubitemid 28428015)
28. Stern RH, Spence JD, Freeman DJ, Parbtani A. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther. 1991;50:66-70.
29. Kobayashi M, Yamamoto M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal. 2005;7:385-394. (Pubitemid 40279806)
30. Henning SM, Swendseid ME, Ivandic BT, Liao F. Vitamins C, E and A and heme oxygenase in rats fed methyl/folate-deficient diets. Free Radic Biol Med. 1997;23:936-942. (Pubitemid 27402619)
31. Paine A, Eiz-Vesper B, Blasczyk R, Immenschuh S. Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem Pharmacol. 2010;80:1895-1903.
32. Lee SE, Jeong SI, Yang H, Park CS, Jin YH, Park YS. Fisetin induces Nrf2-mediated HO-1 expression through PKC- and p38 in human umbilical vein endothelial cells. J Cell Biochem. 2011;112:2352-2360.
33. Liang C, Xue Z, Cang J, Wang H, Li P. Dimethyl sulfoxide induces heme oxygenase-1 expression via JNKs and Nrf2 pathways in human umbilical vein endothelial cells. Mol Cell Biochem. 2011;355:109-115.
34. Watt MJ, Southgate RJ, Holmes AG, Febbraio MA. Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1alpha in human skeletal muscle, but not lipid regulatory genes. J Mol Endocrinol. 2004; 33:533-544. (Pubitemid 39429575)
35. Walters RW, Shukla AK, Kovacs JJ, Violin JD, DeWire SM, Lam CM, Chen JR, Muehlbauer MJ, Whalen EJ, Lefkowitz RJ. Beta-arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest. 2009;119:1312-1321.
36. Tang Y, Zhou L, Gunnet JW, Wines PG, Cryan EV, Demarest KT. Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74a. Biochem Biophys Res Commun. 2006;345:29-37.
37. Shen M, Yen A. Nicotinamide cooperates with retinoic acid and 1,25-dihydroxyvitamin D(3) to regulate cell differentiation and cell cycle arrest of human myeloblastic leukemia cells. Oncology. 2009;76:91-100.
38. Lee TS, Chang CC, Zhu Y, Shyy JY. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation. 2004;110: 1296-1302. (Pubitemid 39202348)
39. Lee TS, Chau LY. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med. 2002;8:240-246.
40. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal. 2000;12:1-13. (Pubitemid 30017963)